Patents by Inventor Wolfgang Glaesner
Wolfgang Glaesner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140024586Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: ApplicationFiled: October 3, 2013Publication date: January 23, 2014Applicant: ELI LILLY AND COMPANYInventors: Tamer COSKUN, Wolfgang GLAESNER
-
Patent number: 8557769Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: GrantFiled: June 27, 2012Date of Patent: October 15, 2013Assignee: Eli Lilly and CompanyInventors: Tamer Coskun, Wolfgang Glaesner
-
Publication number: 20120264683Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: ApplicationFiled: June 27, 2012Publication date: October 18, 2012Applicant: ELI LILLY AND COMPANYInventors: Tamer Coskun, Wolfgang Glaesner
-
Patent number: 8273854Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: October 31, 2008Date of Patent: September 25, 2012Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
-
Patent number: 8183340Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.Type: GrantFiled: May 11, 2006Date of Patent: May 22, 2012Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
-
Publication number: 20110034373Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: ApplicationFiled: July 30, 2008Publication date: February 10, 2011Applicant: ELI LILLY AND COMPANYInventors: Tamer Coskun, Wolfgang Glaesner
-
Publication number: 20090232807Abstract: The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, initable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: ApplicationFiled: December 15, 2005Publication date: September 17, 2009Applicant: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, JR.
-
Publication number: 20090215981Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.Type: ApplicationFiled: May 11, 2006Publication date: August 27, 2009Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, JR., Andrew Mark Vick, Lianshan Zhang
-
Patent number: 7576190Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.Type: GrantFiled: May 2, 2005Date of Patent: August 18, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Yu Tian, Sheng-Hung Rainbow Tschang
-
Patent number: 7557183Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: March 19, 2004Date of Patent: July 7, 2009Assignee: Eli Lilly and CompanyInventors: Richard Dennis DiMarchi, Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
-
Publication number: 20090118190Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: ApplicationFiled: January 6, 2009Publication date: May 7, 2009Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Publication number: 20090074769Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: ApplicationFiled: October 31, 2008Publication date: March 19, 2009Inventors: Wolfgang Glaesner, Rohn Lee Millican, JR., Andrew Mark Vick
-
Patent number: 7498308Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.Type: GrantFiled: May 18, 2006Date of Patent: March 3, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican
-
Patent number: 7491697Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: GrantFiled: December 1, 2004Date of Patent: February 17, 2009Assignee: Eli Lilly and CompanyInventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Patent number: 7482321Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.Type: GrantFiled: January 3, 2003Date of Patent: January 27, 2009Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Wayne David Kohn, Rohn Lee Millican, Lianshan Zhang
-
Patent number: 7452966Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.Type: GrantFiled: June 10, 2004Date of Patent: November 18, 2008Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick
-
Publication number: 20080096811Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.Type: ApplicationFiled: May 19, 2005Publication date: April 24, 2008Applicant: Eli Lilly and CompanyInventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
-
Publication number: 20080026996Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.Type: ApplicationFiled: May 19, 2005Publication date: January 31, 2008Applicant: ELI LILLY AND COMPANYInventors: Bengt Bokvist, Jesper Gromada, Robert Cummins, Wolfgang Glaesner, John Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
-
Publication number: 20070265200Abstract: The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.Type: ApplicationFiled: March 4, 2005Publication date: November 15, 2007Applicant: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Radhakrishnan Rathnachalam, Rohn Millican, Sheng-Hung Tschang
-
Publication number: 20070253966Abstract: The invention provides active therapeutic peptides fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, reduced half antibody formation, and reduced effector activity, while not being immnunogenic. The fusion proteins are useful in treating human diseases as well as a variety of other conditions or disorders.Type: ApplicationFiled: June 10, 2004Publication date: November 1, 2007Applicant: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Rohn Millican Jr, Yu Tian, Sheng-Hung Tschang, Andrew Vick